Skip to main content
Berger's disease treatment gains orphan status

The FDA gave orphan designation to Anthera Pharmaceuticals' blisibimod to treat immunoglobulin A nephropathy, or Berger's disease. Anthera said it could report later this month on a midstage trial of the drug, a B-cell activating factor antagonist.

Full Story: